Search results

Order by most recent / most popular / relevance

Results: 1-10 of 30

Personalized medicine patents at risk: tips for battling Prometheus and Myriad to obtain claims to diagnostics

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
March 14 2013

Imagine a scenario where a pharmaceutical company discovers that a discarded drug candidate, perhaps initially dropped from the pipeline after

Podcast: Eric Raciti and Jeremy Bond on evaluating medical device patents

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
February 25 2013

The medical device sector is heavily influenced by patents. However not all patent portfolios are created equal and evaluating them is crucial to

Protecting personalized medicine inventions

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
February 1 2013

Thanks to improvements in next-generation sequencing techniques and other high-throughput approaches for analyzing biological samples, personalized

U.S. Supreme Court to hear myriad gene patent case

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
December 5 2012

On November 30, 2012, the U.S. Supreme Court agreed to hear the case The Association of Molecular Pathology et al. v. Myriad Genetics, Inc. et al. In this case, the Supreme Court will consider the question of whether human genes can be patented

FTC champions inconsistent positions on the reverse payment settlement debate

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
November 30 2012

Patent litigation in the pharmaceutical industry puts at risk billions of dollars in pharmaceutical sales each year

Marine Polymer's wake: understanding intervening rights and the new U.S. Patent Office Procedures

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
September 15 2012

Intervening rights can shield an alleged infringer from patents whose claims are modified by a post-grant proceeding conducted at the U.S. Patent and Trademark Office (“PTO”

Podcast: Michael J. Flibbert and Marian T. Flatteryon critical considerations for U.S. life sciences patents

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
August 22 2012

With patent cliffs approaching for a number of blockbuster drugs and the America Invents Act coming into effect, life science patents are at the forefront of many executives' minds

Not magic but ingenious: Federal Circuit issues Myriad decision

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
August 17 2012

Isolated DNA encoding disease-causing proteins and drug-screening methods built upon it can meet the threshold test for patent-eligible subject matter under 35 U.S.C. 101 in light of various Supreme Court holdings, “particularly including Mayo.”

Les bookoff and Dinesh Melwani discuss the role of IP in medical device investments and mergers & acquisitions

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
April 4 2012

In the competitive medical device industry, a strong patent portfolio can be one of a device manufacturer’s most valuable assets

Denise DeFranco provides an analysis of the Mayo Collaborative Services v. Prometheus Labs U.S. Supreme Court decision

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
-
USA
-
March 29 2012

The Supreme Court of the United States recently issued its decision in the case Mayo Collaborative Services v. Prometheus Labs

next >